Clinical evaluation working guide
MEDDEV 2.7/1 Rev 4 vs MDR: What Changes for a CER?
MEDDEV 2.7/1 Rev 4 is clinical evaluation guidance developed under the earlier medical device directives. The MDR is binding legislation. Familiar MEDDEV methods can remain useful where applicable, but following its structure does not by itself establish an MDR clinical evaluation.
The practical question is not whether to delete every MEDDEV reference. It is whether the evaluation addresses the current device, applicable MDR requirements and relevant guidance, with clear evidence and reasoning.
Compare the role of each document
MEDDEV describes a staged evaluation method, including scope, data identification, appraisal, analysis and reporting. It offers methodological detail that can help explain how work was performed. Its origin under the directives matters when interpreting references to the former Essential Requirements.
The MDR establishes the applicable legal requirements. Where guidance and the MDR diverge, the MDR takes precedence. MDCG documents address particular implementation questions; their titles and scope should be checked before applying them. A reference list containing many guidance numbers does not show that the relevant issue has actually been evaluated.
Review the substance rather than replacing labels
For an existing CER, build a crosswalk with the current requirement or evaluation question, the report location, supporting record and required action. Review the intended purpose, claims, populations and evaluated configurations first; otherwise an apparently complete crosswalk can describe the wrong device.
One useful check is whether the report explains the relationship between a claimed clinical benefit and the measured outcomes. Another is whether the current state of the art affects the interpretation of the available data. These are questions for the evidence analysis, not problems solved by replacing MDD terminology with MDR terminology.
Keep similar-device context separate from equivalence
A literature review can use similar-device studies to describe clinical context without making those devices equivalent. When another device’s clinical data are relied on through an equivalence argument, that argument needs its own assessment. See the MDCG 2020-5 equivalence guide for a practical evidence-access checklist.
The crosswalk should identify the role assigned to each evidence source. Otherwise a background study may quietly become the principal support for a device claim. Explain the reasoning and limitations at the point where the evidence is used.
Legacy status and lifecycle maintenance
MDCG 2020-6 specifically addresses clinical evidence for devices previously CE marked under the directives. Historical data should be assessed for their contribution to the present evaluation. A previous certificate or earlier report cannot replace an appraisal of relevance and quality.
Clinical evaluation also needs a path for new evidence and changed conclusions. Identify the source period, reporting dependencies and review triggers so the CER remains connected to postmarket records. The IMTS document-alignment article explains how to keep the related reports consistent.
Choose the right correction project
If the evaluation needs a full reassessment for transition, a legacy-device scope is more useful than a simple editorial update. If the baseline is sound and a new evidence period is due, a CER update may be sufficient. If a notified body has raised findings, organize the response around those exact findings and their supporting revisions.
Before commissioning work, send the existing report, plan, source records and current claims. Ask the writer to identify which assumptions can be retained, which need reanalysis and which cannot be resolved without manufacturer input or further evidence.
Common questions
Does MEDDEV 2.7/1 Rev 4 still have a role?
Its methods can remain useful where applicable. It is guidance under the earlier directives, and the MDR takes precedence where requirements differ.
Is an MDD-era CER automatically suitable for MDR?
No. Reassess its scope, methods, evidence and conclusions against applicable MDR requirements and relevant current guidance.
Must every MEDDEV reference be removed?
Not necessarily. Explain why the cited method remains applicable and do not use guidance to override MDR requirements.
Primary regulatory sources
- MEDDEV 2.7/1 Rev 4: clinical evaluation guidance
- Regulation (EU) 2017/745: Article 61, Annex XIV and Article 120
- MDCG 2020-6: sufficient clinical evidence for legacy devices
- MDCG 2020-5: clinical evaluation equivalence
Check the applicable consolidated legislation and current guidance for the device. Guidance supports interpretation; it does not replace the MDR or a device-specific assessment.
Connected services and working guides
For the complete evaluation package, see IMTS Clinical Evaluation Report writing services.
- Legacy Device CERs for the MDD-to-MDR Transition
- Demonstrating Equivalence Under MDR: MDCG 2020-5 Checklist
- CER Update Services for EU MDR
For an existing directive-era evaluation, explore legacy device CER and MDD-to-MDR support. The main CER writing page covers the broader IMTS service.
Book a Scoping Call